- Published at
- by manilatimes.net
mixed
mixed
News for Torii Pharmaceutical Co., Ltd. (4551.T)
- Published at
- by investing.com
positivepositiveVerrica Pharmaceuticals CEO sells over $230k in company stock By Investing.com
Verrica Pharmaceuticals CEO sells over $230k in company stock- Published at
- by investing.com
positivepositiveVerrica Pharmaceuticals executive sells over $180k in stock By Investing.com
Verrica Pharmaceuticals executive sells over $180k in stock- Published at
- by investing.com
mixedmixedVerrica pharmaceuticals CMO sells over $130k in stock By Investing.com
Verrica pharmaceuticals CMO sells over $130k in stock- Published at
- by investing.com
positivepositiveVerrica Pharmaceuticals amends credit terms By Investing.com
Verrica Pharmaceuticals amends credit terms- Published at
- by marketscreener.com
mixedmixedTorii Pharmaceutical : Positive Top line Results of Phase 3 Clinical Study (Comparative Study) of JTE 061 (tapinarof) Cream, Aryl hydrocarbon Receptor (AhR) agonist, in Pediatric Patients with Atopic
FOR IMMEDIATE RELEASE Tokyo, May 31, 2024 Positive Top-line Results of Phase 3 Clinical Study of JTE-061 Cream, Aryl hydrocarbon Receptor ...- Published at
- by globenewswire.com
positivepositiveVerrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the T
Global pivotal Phase 3 clinical trial would be conducted jointly by Verrica and Torii Pharmaceutical; trial expected to begin in the 1st half of 2025 ...- Published at
- by globenewswire.com
mixedmixedVerrica Pharmaceuticals Reports First Quarter 2024 Financial Results
– Reports YCANTH® revenue of $3.2M for first quarter of 2024 – – Over 228 million lives now covered to date on commercial insurance, managed Medicaid,...- Published at
- by marketscreener.com
mixedmixedVerrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
– Reports YCANTH™ revenue of $1.9M for fourth quarter and $4.7M for full year 2023 – – Over 200 million lives now covered on commercial insurance and managed Medicaid plans – –...- Published at
- by globenewswire.com
mixedmixedVerrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
– Reports YCANTH™ revenue of $1.9M for fourth quarter and $4.7M for full year 2023 – – Over 200 million lives now covered on commercial insurance and...- Published at
- by marketscreener.com
mixedmixedToray Industries : Partner Begins Selling REMITCH® OD Tablets 2.5 µg for Pruritus Treatment in Korea
HOME Newsroom Toray Partner Begins Selling REMITCH® OD Tablets 2.5 µg for Pruritus Treatment in Korea ... | January 17, 2023- Published at
- by etfdailynews.com
mixedmixed- Published at
- by insidermonkey.com
mixedmixed